drugset / Trial / NCT05701527
A Study of EBC-129 in Advanced Solid Tumours
Phase 1
Recruiting
98 enrolled
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Parexel · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
Timeline
- Start
- 2023-04-28
- Primary completion
- 2026-12-24
- Completion
- 2026-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBC-129 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |